<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049790</url>
  </required_header>
  <id_info>
    <org_study_id>ANG-CL-004</org_study_id>
    <nct_id>NCT00049790</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein&#xD;
      administered in combination with paclitaxel and carboplatin to patients with non-small-cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date>December 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human Angiostatin protein</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural&#xD;
             effusions, or Stage IV NSCLC or recurrent NSCLC&#xD;
&#xD;
          -  No previous chemotherapy for NSCLC&#xD;
&#xD;
          -  Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT&#xD;
             greater than 1 cm in diameter&#xD;
&#xD;
          -  Specified lab parameters&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Understand requirements of study&#xD;
&#xD;
          -  Agree to use effective contraceptive methods&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Have CNS metastases&#xD;
&#xD;
          -  Have any active cancer in addition ot NSCLC&#xD;
&#xD;
          -  Participated in clinical trial involving conventional or investigational drugs within&#xD;
             previous 4 weeks&#xD;
&#xD;
          -  Have any contraindication to paclitaxel or carboplatin&#xD;
&#xD;
          -  Have had Grade 3 or greater peripheral neuropathies&#xD;
&#xD;
          -  Be pregnant or lactating&#xD;
&#xD;
          -  Have a history of myocardial infarction or angina pectoris/angina in the last 6 months&#xD;
&#xD;
          -  Have had significant (30 mL or more) hemoptysis with the past 3 months&#xD;
&#xD;
          -  Have an active infection&#xD;
&#xD;
          -  Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding&#xD;
             disorder&#xD;
&#xD;
          -  Be receiving concurrent treatment with therapeutic doses of heparin or coumadin&#xD;
&#xD;
          -  Have had major surgery within 4 weeks of stating therapy&#xD;
&#xD;
          -  Have additional uncontrolled serious medical conditions or psychiatric illness&#xD;
&#xD;
          -  Received rhAngiostatin in other clinical protocols&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana Cancer Pavilion, Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>November 13, 2002</study_first_submitted>
  <study_first_submitted_qc>November 14, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2002</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2009</last_update_posted>
  <keyword>Advanced non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Angiostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

